Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. - Wikidata - awgldk - TriplyDB

Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.

Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.

http://www.wikidata.org/entity/Q33248410

about

Polymers for improving the in vivo transduction efficiency of AAV2 vectors The structure of adeno-associated virus serotype 3B (AAV-3B): Insights into receptor binding and immune evasion Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adeno-associated virus E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X Applying gene silencing technology to contraception Targeted gene silencing to induce permanent sterility Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy.Current and emerging treatments and surgical interventions for Morquio A syndrome: a review A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.A NEW RECOMBINANT ADENO-ASSOCIATED VIRUS (AAV)-BASED RANDOM PEPTIDE DISPLAY LIBRARY SYSTEM: INFECTION-DEFECTIVE AAV1.9-3 AS A NOVEL DETARGETED PLATFORM FOR VECTOR EVOLUTION.Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter.Adeno-associated virus-like particles as new carriers for B-cell vaccines: testing immunogenicity and safety in BALB/c mice Chondroitin Sulfate is the Primary Receptor for a Peptide-Modified AAV That Targets Brain Vascular Endothelium In Vivo.Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate.Biomathematical description of synthetic peptide libraries.Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy Optimization of design and production strategies for novel adeno-associated viral display peptide libraries.Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors Novel vectors for in vivo gene delivery to vascular tissue.Viral vectors: from virology to transgene expression Characterization of interactions between heparin/glycosaminoglycan and adeno-associated virus.Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8.Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions.Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer.Next-generation AAV vectors for clinical use: an ever-accelerating race.Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors.Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS A directed evolution approach to select for novel Adeno-associated virus capsids on an HIV-1 producer T cell line.Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis.

P2860

Q27438107-F8CCAFFE-77FC-46F1-A5FF-11CF5D27E690 Q27661320-8A87628F-99A3-46D9-88B4-28AF4C214CE2 Q27679952-DD4E87CC-5F2F-4464-B125-20CAA8FEC01A Q28083324-18A59E0A-049C-4233-B733-09CF65BA6080 Q28475714-35429729-C4EA-4F30-8FE5-220CA71CF1D0 Q28703567-1AA01759-7832-445A-9654-9B138FB2DC45 Q28710390-FD3A6402-D5C6-4557-8A4C-635B07FCB013 Q33296224-527C1FC9-97BE-4A61-AA30-E1AE99A4D353 Q33327474-4940BAA8-902E-4996-A7DE-45E81FF90A38 Q33428576-F657D473-2CCC-4C96-AB4B-41A3EF5CAB45 Q33502598-9D6EC5A8-244E-4F20-A111-1301E144D550 Q33587005-EE84F7EF-4A45-4963-B9EE-EF25E4CDD18B Q33610398-AF3A3AD5-5F70-488E-9409-E4D14A3A142C Q33711477-E1DCF65D-ADDC-412E-8006-A11D3F83E938 Q33739804-20A19698-204D-4636-A450-83260E11E25A Q33908400-33758BCF-7335-4DA0-ACB3-E5D4B5BB1755 Q33995646-EEBB068E-847B-47C3-A8B0-AAFFCA56485A Q34025091-C866DB9C-C5D6-420F-8085-F799D04725BF Q34342494-AD63BC96-4F16-4F90-B236-7CF08C84C8E5 Q34440125-CAF88E8F-1AEB-4BDB-B9A6-FBECBC527A20 Q34440312-3336059A-DC6E-4158-90B4-EBF6D91B25A5 Q35107329-4F1A3A8E-BDC7-4741-BC54-50E7A37F54B4 Q35652428-9EF766CA-4E00-4178-B25F-801C4D63C361 Q35661179-6FFA9AB9-7325-4F5D-8508-8F750CC10DED Q36406869-EA0014A5-6ABD-46FF-A9FF-9428D3F3AC80 Q36407303-F3F5ABCD-8363-4B7C-B8BE-A083415D8A4F Q36433979-78257B35-0402-4C65-B963-BF91D447F688 Q36736418-14F56F7D-993A-4714-9E73-01F5A21EF169 Q36842711-AC16F34A-30AE-4463-B10D-D3783D03FA3C Q37262766-21080F8A-701D-4ED0-95D1-C50D0B17D27C Q37385088-77E488F2-9B5F-49A7-B582-D0A311C9592D Q37731803-00D1A433-B33A-4151-838F-31F74AC695EC Q39130497-93CE2897-B185-42E6-93C0-A1B049B7A719 Q40051540-4D59B648-345F-45E0-936A-39DACE102D4F Q40097321-3BC69DDA-24CF-4481-9123-E9879C29F8DF Q40100060-C4B0C8E6-1534-41CC-939F-ABFA9502CAAD Q41493938-5DD42D43-C687-4B40-9ED0-7A1098F67F64 Q41647072-22AFCE40-A996-43C8-ADF9-1EF852869D60 Q41936136-2FEB2403-3B60-4EAC-84BF-E1F3310FD6B9 Q45870768-CF5124FA-EA71-4C76-993C-F23BEBA52D48

P2860

Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.

http://www.wikidata.org/entity/Q33248410

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Heparan sulfate proteoglycan b ...... ces for their in vivo tropism.

@ast

Heparan sulfate proteoglycan b ...... ces for their in vivo tropism.

@en

type

label

Heparan sulfate proteoglycan b ...... ces for their in vivo tropism.

@ast

Heparan sulfate proteoglycan b ...... ces for their in vivo tropism.

@en

prefLabel

Heparan sulfate proteoglycan b ...... ces for their in vivo tropism.

@ast

Heparan sulfate proteoglycan b ...... ces for their in vivo tropism.

@en

P1433

Q33248410-5C846C8F-2359-4899-A06F-217ADAFCBA7A

P1476

Q33248410-2E57EC68-105E-4AC2-8C3C-15ABB1F2414C

P2093

Q33248410-0FA37332-430F-419C-B97D-811464AB8EFD

Q33248410-1BFDB80F-6197-4F17-BF03-6C04974BC1E6

Q33248410-5111023D-E4CC-4915-9F44-ACC76DBB4899

Q33248410-75B78712-2AB4-4620-AB5E-D12B9C09BBE5

Q33248410-8EFE6838-4CFB-482F-B028-C4851C7B5B7B

Q33248410-9A45360D-8AA7-46D7-A6B7-3B8B9C894228

Q33248410-A4343DA2-159B-4C78-BD11-61BDDF596C98

Q33248410-A9438211-20F4-4BF5-98AE-64F2A81CB64A

Q33248410-C3558D44-5480-4ADA-B429-2EFBF0AC1F55

P2860

Q33248410-1887AE2A-448C-4160-A531-8F8652D75781

Q33248410-1A6F2F79-A469-463F-8809-B9E349EE473F

Q33248410-28CE6AB1-0559-498F-92E5-70AA8DCF7DD1

Q33248410-361693B4-F26E-416C-86C5-40013594D483

Q33248410-4E26127C-7064-492B-B7E4-02BAFBD97F02

Q33248410-5AB546F1-A36A-43EA-92D3-29C9F99B5483

Q33248410-8609EA86-EA16-47BE-9471-2D784D170751

Q33248410-899737C3-970C-4F6D-AE31-7D1570B4091B

Q33248410-9E06A818-DF2E-4F71-8ACD-23338456101F

Q33248410-C584BB8C-B2B3-4089-A3C4-BDC7A83E0E8B

P304

Q33248410-CEBB43D7-F773-48B3-8EC6-1055E0647199

P31

Q33248410-4F988CD5-0552-43E7-B309-F26FA90E00A1

P356

Q33248410-B42BB035-BD02-4A52-88B7-C02BF12F647A

P433

Q33248410-C7354D8A-9138-4D9D-8626-ECADD7E0CE8D

P478

Q33248410-2D37429B-27AB-4265-BAA6-FA4E370BF4A7

P50

Q33248410-206B742F-7484-4167-B262-34B64A34B776

Q33248410-D1EDF639-3506-4AB0-B9CF-8BF68BC0C07E

P577

Q33248410-D76681A6-C8A4-46D0-8D7F-964CBB9758B9

P698

Q33248410-6D787EE3-F35B-49CB-8FC7-1239AFCB3A06

P932

Q33248410-26FB95B1-346E-45DA-ADE1-1DD92F7B8650

P356

P1433

Journal of Virology

P1476

Heparan sulfate proteoglycan b ...... ces for their in vivo tropism.

@en

P2093

Andrew H Baker

http://www.w3.org/2001/XMLSchema#string

Daniela Goldnau

http://www.w3.org/2001/XMLSchema#string

Hanna Janicki

http://www.w3.org/2001/XMLSchema#string

Hildegard Büning

http://www.w3.org/2001/XMLSchema#string

Jan Endell

http://www.w3.org/2001/XMLSchema#string

Jorge Boucas

http://www.w3.org/2001/XMLSchema#string

Kathryn White

http://www.w3.org/2001/XMLSchema#string

Luca Perabo

http://www.w3.org/2001/XMLSchema#string

Sibille Humme

http://www.w3.org/2001/XMLSchema#string

P2860

Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors.

In vitro selection of viral vectors with modified tropism: the adeno-associated virus display.

Development of efficient viral vectors selective for vascular smooth muscle cells.

Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses.

Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.

Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors.

Receptor targeting of adeno-associated virus vectors.

AAV-based gene transfer.

P304

7265-7269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.00076-06

http://www.w3.org/2001/XMLSchema#string

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P50

Lorraine M Work

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16809332

http://www.w3.org/2001/XMLSchema#string

P932

1489073

http://www.w3.org/2001/XMLSchema#string